Dec 4, 2008 ... Federal Trade Commission, Plaintiff, v. Mystery Shop Link, LLC, a Maine Limited
Liability Company, Tangent Group, LLC, a Maine Limited ...
with the case captioned FTC v. Stratified Advertisina and. Marketinq, Inc., et al.,
Civ. No. ... "Defendants" means Mystery Shop Link, LLC, Tangent. Group, LLC ...
v. MYSTERY SHOP LINK, LLC, a Maine Limited Liability. Company,. TANGENT
GROUP, LLC, a Maine Limited Liability. Company,. ROBIN LARRY MURPHY,.
Nov 4, 2013 ... Since clinical equipoise exists between adjuvant versus early salvage post-
operative ..... Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP et al. (2004)
... Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G et al.
Feb 28, 2012 ... Thereby, the distinction of local versus systemic tumor progression is not
compromised, and additional side effects can be avoided. ... Trock et al. analyzed
635 patients undergoing RP in the years of 1982 to ..... Thompson IM, Jr., Tangen
CM, Paradelo J, et al. .... Pisansky TM, Kozelsky TF, Myers RP, et al.
Nov 15, 2006 ... ... median survival of 14.7 years for radiotherapy vs 83 deaths, median survival of
13.8 ... Ian M. Thompson, MD; Catherine M. Tangen, DrPH; Jorge Paradelo, MD;
M. Scott Lucia, ..... Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute
ML. ... Eisenberger MA, Blumenstein BA, Crawford ED. et al.
Mar 10, 2014 ... Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink
, Tong Xu, ... versus five per 7.5 mL were significantly associated with baseline
..... IMMC (Immunicon) 38 cohort previously reported by de Bono et al,9 ..... Bristol
-Myers Squibb, Active BioTech, Novartis, Exelixis, Medivation;.
Apr 30, 2012 ... Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for
pathological T3N0M0 prostate cancer significantly reduces risk of ...
Dec 6, 2005 ... D., M.B.A.<sup>3</sup> and; Anthony V. D'Amico M.D., Ph.D.1,†,* ..... In 1989, Ferro et al.22
reported that post-treatment PSA changes were clinically relevant indicators of
response in patients with ... Zincke H, Oesterling JE, Blute ML, Bergstralh EJ,
Myers RP, Barrett DM. ... Crawford ED, Pauler DK, Tangen CM, et al.
ET AL. Maximizing outcomes in genitourinary cancers across the treatment
continuum. John M. Fitzpatrick* ... randomized trials vs current standards of care.